# A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed in the Body Compared to an Old Tablet and How Food Affects the Way the New Tablet is Absorbed and Processed in the Body

> **NCT07722585** · PHASE1 · RECRUITING · sponsor: **Bayer** · enrollment: 18 (estimated)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Nurandociguat (BAY3283142) old tablet - SD
- **DRUG:** Nurandociguat (BAY3283142) new tablet - SD
- **DRUG:** Nurandociguat (BAY3283142) old tablet
- **DRUG:** Nurandociguat (BAY3283142) new tablet

## Key facts

- **NCT ID:** NCT07722585
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-28
- **Primary completion:** 2026-10-07
- **Final completion:** 2026-10-07
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07722585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07722585, "A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed in the Body Compared to an Old Tablet and How Food Affects the Way the New Tablet is Absorbed and Processed in the Body". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07722585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*